<DOC>
	<DOCNO>NCT00652041</DOCNO>
	<brief_summary>Multicentric study , open , single arm , design evaluate efficacy ( response rate response duration ) security sequential scheme treatment Bortezomib combination Melfalan Prednisone ( V-MP ) ( patient &gt; 75 year ) Bortezomib Adriamycine combination Melfalan Prednisone ( VAMP ) ( patient &lt; = 75 year ) follow Thalidomide combination Cyclophosphamide Dexamethasone ( TaCyDex ) patient refractary relapse multiple myeloma .</brief_summary>
	<brief_title>Bortezomib/Adriamycine/Melfalan/Prednisone ( VAMP ) /Thalidomide/Cyclophosphamide/Dexamethasone ( TaCyDex ) Bortezomib/Melfalan/Prednisone ( V-MP ) /TaCyDex ) Refractary Relapsed Multiple Myeloma</brief_title>
	<detailed_description>Multicentric study , open , single arm , design evaluate efficacy ( response rate response duration ) security sequential scheme treatment Bortezomib combination Melfalan Prednisone ( V-MP ) ( patient &gt; 75 year ) Bortezomib Adriamycine combination Melfalan Prednisone ( VAMP ) ( patient &lt; = 75 year ) follow Thalidomide combination Cyclophosphamide Dexamethasone ( TaCyDex ) patient refractary relapse multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients refractary relapse multiple myeloma ECOG ≤ 3 Life expectancy &gt; 3 month Neutrophils account ≥ 0.5 X 10^9/L , platelet ≥ 30 X 10^9/L . Transaminases &lt; 3 time upper normal limit , bilirubin &lt; 2 time upper normal limit Age &gt; 18 year Time last chemotherapy radiotherapy &gt; 1 month time transplantation &gt; 2 month . No possible actual treatment Written consent form Candidate second transplantation No follow criterion Other neoplasties Peripheral neuropathy &gt; Grade 2 . Previous ileus paralytic Hepatic failure No control infection No control high calcium level Any organic insufficiency permit follow correct treatment Pregnancy , breast feeding fertility without anticonceptive method Any psychological , social and/or familiar event permit follow correct treatment Diabetes mellitus control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractary</keyword>
</DOC>